G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)

October 10, 2022

https://www.globenewswire.com/news-release/2022/10/10/2530822/0/en/G1-Therapeutics-Completes-Enrollment-in-Global-Multi-Center-Phase-3-Clinical-Trial-of-Trilaciclib-in-Patients-with-Metastatic-Triple-Negative-Breast-Cancer-TNBC.html

RESEARCH TRIANGLE PARK, N.C., Oct. 10, 2022 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the last patient has been randomized in PRESERVE 2, G1’s Phase 3 clinical trial of trilaciclib in patients with metastatic triple negative breast cancer (TNBC) receiving chemotherapy. The trial includes 187 patients receiving first line trilaciclib or placebo prior to gemcitabine and carboplatin (GC).

Read more at globenewswire.com

Related news for (GTHX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.